Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Byetta, Exenatide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| glp-1-analogue | ACTIVE_COMPARATOR | During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned |
| placebo | PLACEBO_COMPARATOR | During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned. |
| Name | Type | Description |
|---|---|---|
| Byetta, Exenatide | DRUG | Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once |
Inclusion Criteria: * Informed consent signed * Caucasian * Male * Diabetes for \> 6 months * Diet treatment or a single OAD (metformin, SU) * Age \> 50 years and \< 70 years * BMI 20-45 kg/m² * Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 11% inclusive. * Fasting PG 7...
Top 20 of 31 competitors
Byetta (exenatide) is used for the treatment of Type 2 Diabetes. It is a small molecule being developed by Eli Lilly and Company. The drug is currently in Phase 2 clinical development for this indication, and it is considered investigational, meaning it has not yet been approved for use.
Byetta (exenatide) works as a GLP-1 analogue, which means it mimics the action of the naturally occurring hormone GLP-1. This mechanism is being studied for its effects on Type 2 Diabetes, particularly in the central nervous system and heart during hyperglycemia, as assessed in clinical trials.
Byetta (exenatide) is developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes.
Byetta (exenatide) is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of Type 2 Diabetes, and its clinical trial program is ongoing.
Byetta (exenatide) has been studied in a Phase 2 clinical trial with the identifier NCT00747968. This completed trial, titled "The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET," enrolled 8 male participants aged 50 years and older in Denmark. The trial was randomized, double-blind, and placebo-controlled.
Yes, Byetta is the same as exenatide. Byetta is a brand name, and exenatide is the generic name for the drug. Both names refer to the same medication being developed by Eli Lilly and Company for the treatment of Type 2 Diabetes.